Examkin

Question

Difficulty: HardEndocrinology and Metabolism

A 6262-year-old man comes to the clinic for a routine follow-up. Eight weeks ago, he was hospitalized for new-onset atrial fibrillation and was successfully converted to normal sinus rhythm. He was discharged on a regimen of amiodarone and apixaban. Today, the patient reports feeling well with no palpitations, shortness of breath, heat intolerance, weight changes, fatigue, or constipation. His pulse is 6868/min and regular, and his blood pressure is 124/78124/78 mm Hg. Physical examination shows a normal-sized, non-tender thyroid gland with no palpable nodules. There is no resting tremor.

Laboratory studies show the following:
Thyroid-stimulating hormone (TSH): 7.87.8 μ\mu U/mL (Normal: 0.5−5.00.5-5.0 μ\mu U/mL)
Free thyroxine (T4): 2.12.1 ng/dL (Normal: 0.9−1.70.9-1.7 ng/dL)
Free triiodothyronine (T3): 1.61.6 pg/mL (Normal: 2.3−4.12.3-4.1 pg/mL)

Which of the following is the most appropriate next step in the management of this patient's thyroid function?

  1. Continue current management and repeat thyroid function tests in 12 weeksAnswer
  2. B
    Discontinue amiodarone and switch to an alternative antiarrhythmic agent
  3. C
    Initiate therapy with low-dose levothyroxine
  4. D
    Initiate therapy with methimazole
  5. E
    Perform a radioactive iodine uptake scan

Answer

Continue current management and repeat thyroid function tests in 12 weeks
The correct answer is to continue current management and observe. Amiodarone is an iodine-rich antiarrhythmic drug that exerts multiple physiological effects on the thyroid axis. One of its primary effects is the inhibition of 5'-deiodinase, the enzyme responsible for the peripheral conversion of thyroxine (T4) to the more active triiodothyronine (T3). This inhibition results in an elevation of serum free T4 and a reduction in serum free T3. Because T3 is the primary hormone providing negative feedback to the hypothalamus and pituitary, the transient drop in T3 leads to a compensatory increase in thyroid-stimulating hormone (TSH). This classic physiological profile (mildly elevated TSH, elevated free T4, and low-normal or low free T3) typically peaks within the first 1 to 3 months of amiodarone therapy. Since the patient is entirely asymptomatic and euthyroid, this pattern does not represent true hypothyroidism or thyrotoxicosis. No medical intervention is required, and the TSH will typically normalize over the next 3 to 6 months as a new steady state is achieved.

Step-by-Step Solution

1
Analyze the patient's symptoms and vital signs in the context of his recent medication changes.
The patient is completely asymptomatic, has normal vital signs, and was started on amiodarone 8 weeks ago.
Establishing the clinical status (euthyroid) is crucial before interpreting laboratory abnormalities.
2
Interpret the thyroid function test profile.
The labs show a mildly elevated TSH, an elevated free T4, and a low free T3.
Identifying the specific pattern of hormone alterations helps differentiate between true thyroid disease and medication effects.
3
Correlate the lab profile with the physiological effects of amiodarone.
The pattern matches the expected 5'-deiodinase inhibition caused by amiodarone early in therapy.
Amiodarone predictably decreases peripheral T4 to T3 conversion, leading to transient TSH elevation due to reduced T3-mediated negative feedback.
4
Determine the appropriate clinical intervention.
Observation and repeat testing is selected.
Because these changes are physiologic and the patient is euthyroid, no active medical intervention or drug discontinuation is required.

Key Concept

Early physiologic thyroid function alterations secondary to amiodarone therapy
Estimated Time:1m 30s
Rate this question

Topics

Endocrinology and Metabolism

More questions from this topic